ArticleBMC medical imaging2026
Development and validation of an MRI-based clinical-radiomics nomogram for predicting lymph node metastasis in non-small cell lung cancer.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTo develop and validate a nomogram that integrates clinical factors and multiparametric MRI-based radiomics features for the preoperative prediction of lymph node metastasis (LNM) in non-small cell lung cancer (NSCLC).
methodsThis retrospective diagnostic accuracy study enrolled 220 patients with pathologically confirmed NSCLC (142 males; 60.77 ± 8.70 years) between September 2021 and October 2024. Patients were randomly divided into training and validation sets. A clinical model was constructed using independent predictors identified by univariable and multivariable logistic regression analysis. A radiomics signature was developed from T1WI, T2WI, and T1 mapping sequences using the least absolute shrinkage and selection operator logistic regression algorithm. A nomogram was developed by integrating the clinical model and the radiomics signature. Diagnostic performance was assessed by receiver operating characteristic analysis, calibration, and decision curve analysis. Two radiologists independently assessed LNM status in the validation set for comparison.
resultsTumor maximum diameter and carcinoembryonic antigen level were identified as independent predictors for the clinical model. In the validation set, the nomogram achieved an area under the curve (AUC) of 0.847, significantly greater than the clinical model (AUC = 0.710, p = 0.033) and the radiomics signature alone (AUC = 0.802, p = 0.033). The AUC of the nomogram was significantly higher than two radiologists (0.847 vs. 0.682, p = 0.022; 0.847 vs. 0.698, p = 0.041, respectively).
conclusionThe nomogram could serve as a noninvasive tool for preoperative prediction of LNM in NSCLC, thereby aiding in clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.